Skip to main content

Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Publication ,  Other
Gupta, S; Halabi, S; Yang, Q; Roy, A; Tubbs, A; Gore, Y; George, DJ; Nanus, DM; Antonarakis, ES; Danila, DC; Szmulewitz, RZ; Wenstrup, R ...
May 15, 2023

<p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).</p>

Duke Scholars

DOI

Publication Date

May 15, 2023
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gupta, S., Halabi, S., Yang, Q., Roy, A., Tubbs, A., Gore, Y., … Armstrong, A. J. (2023). Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. https://doi.org/10.1158/1078-0432.22820158.v1
Gupta, Santosh, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, et al. “Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer,” May 15, 2023. https://doi.org/10.1158/1078-0432.22820158.v1.
Gupta S, Halabi S, Yang Q, Roy A, Tubbs A, Gore Y, George DJ, Nanus DM, Antonarakis ES, Danila DC, Szmulewitz RZ, Wenstrup R, Armstrong AJ. Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. 2023.

DOI

Publication Date

May 15, 2023